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Abstract The overproduction of ~amyloid (A~) appears to be a 
primary cause of Alzheimer's disease (AD). Ap can be generated 
by proteolytic leavage of precursor protein (pAPP) at I~ and 7- 
secretasc sites in both disease and normal cells. There is, 
however, no evidence that proteolytic processing of ~APP in 
sporadic AD-affected tissues differs qualitatively or quantita- 
tively from that occurring in normal cells, and additional 
pathways for the enhanced production of A~ in sporadic AD 
which constitutes the majority of all AD cases should be 
considered. The major factor limiting the production of A~ in 
normal cells is cleavage at the ~t-secretase site within the A~ 
sequence. But, whereas the intact ~APP is a substrate for 
cleavage at the ~secretase site, the immediate precursor of Ap, 
12-kDa C-terminal ~APP fragment, is not susceptible to the 
ot-secretase cleavage but it can be cleaved by ~secretase thus 
generating A~. Moreover, the 7-secretase cleavage is not the rate- 
limiting step in the production of A~. Therefore, the increase in 
production of the 12-kDa C-terminal ~APP fragment may be an 
efficient way to overproduce A~. A mechanism for the generation 
of the 12-kDa fragment independently of pAPP is proposed. It 
postulates an additional step of amplification of mRNA, namely 
the antisense RNA-mediated generation of a truncated mRNA 
encoding 12-kDa C-terminal fragment. Initiation of translation 
at the first AUG in the truncated mRNA results in a polypeptide 
that is cleaved by ~'-secretase generating Ap. The proposed model 
makes several verifiable predictions and suggests new directions 
of experimentation that may lead to a better understanding of the 
mechanisms involved in AD. 
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cells from patients with a defect in the S182 gene, associated 
with the most common form of the early-onset AD, make 
abnormally high amounts of Ap [5]; Down syndrome, asso- 
ciated with trisomy 21 and, consequently, increased osage of 
the 13APP gene which is located on chromosome 21, is char- 
acterized by increased levels of pAPP gene expression and by 
the early cerebral deposition of AI~ [6,7]. The most convincing 
evidence for the notion that overproduction of Ap is sufficient 
to trigger AD comes from experiments with transgenic mice 
overexpressing full-length human pAPP, which generate high 
levels of AI~ and develop AD-like neuropathology [8]. 
AI~ can be produced by proteolysis of pAPP, a process that 
occurs constitutively in both normal and AD-affected tissues 
as well as in cultured cells [8-12], and its overproduction i
AD is currently explained in terms of proteolytic processing of 
I~APP. pAPP proteolysis is effected by yet to be identified 
enzymes designated t~-, [~- and y-secretases (Fig. 1) and oc- 
curs at Met596/Asp 597 (13-secretase; pAPP695 numbering), at 
Lys612/Leu 613 (ct-secretase) and between Va1635 and Thr 639 
(y-secretase). Cleavage by 13-secretase g nerates an ectodomain 
fragment ending at Met ~96 and a 12-kDa C-terminal [~APP 
fragment containing AI~ at its N-terminus (beginning with 
AspS97). The production of A~ by proteolysis of ~APP re- 
quires cleavage by both ~- and ~(-secretases. Cleavage by ~t- 
secretase generates an ectodomain fragment ending at Lys 612 
and precludes formation of AI~ because it occurs within the AI~ 
sequence. Mutations within the pAPP gene that affect I~APP 
proteolytic pathway are responsible for overproduction of Ap 
and, consequently, for increased generation of AI~ deposits in 
some types of familial AD. In such familial AD cases, muta- 
1. Introduction 
The accumulation of 13-amyloid (AI~), a small 4-kDa seg- 
ment in the C-terminal portion of ~l-amyloid precursor protein 
(pAPP), is associated with and considered by many to be the 
primary cause of Alzheimer's disease (AD) [1]. Although the 
accumulation of AI~ might be due to its increased aggregation 
or decreased clearance, recent results from a number of in- 
vestigators strongly suggest that the overproduction of AI~ is, 
in fact, the major cause of its accumulation and, consequently, 
of AD. The notion of the causative role of Ap overproduction 
in AD is supported by several types of results: a number of 
mutations in the pAPP gene that underlie some forms of fa- 
milial AD were found to increase the production of A~ [24]; 
*Corresponding author. Fax: (1) (617) 523-6649. 
O~oSECRETASE 
~-SECRETASE. i '7"SECRETASE 
N., I 0oo, 
. 11 ! 
i 13-AMYLOID "~ ~ [ 
, I 
~ 12kDa C-TERMINAL ~APP FRAGMENT -~ T-'--- '] 
I 
t t 
I~-AMYLOID PRECURSOR PROTEIN (I~APP) 
Fig. I. In-scale schematic diagram of the ~APP and its proteolytic 
processing pathways. In the amyloidogenic pathway (solid vertical 
arrows), cleavage at the ~-secretas¢ site generates 12 kDa C-terminal 
~APP fragment, he immediate precursor of Ap; cleavage of the 12 
kDa fragment at the 7-secretase ite results in A~. In the non-amyl- 
oidogenic pathway (dashed arrow), cleavage at the ct-secretase ite 
precludes formation of A~ because it occurs within the AI~ segment. 
See details in text. 
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tion-mediated enhancement or alteration of proteolytic leav- 
age of pAPP is sufficient for an accelerated cerebral deposition 
of Ap and there is no need to invoke an additional mechanism 
beside the mutations. For example, the naturally occurring 
Flemish mutation (Ala 616 to Gly 616) as well as the genetically 
engineered mutation Phe 614 to Pro 614 interfere with the clea- 
,~ age of ~APP at the ~x-secretase ite and, consequently, in- 
rease the production of Ap [3,13]. Probably the best example 
~s proteolytic processing of ~APP containing the mutation 
~ys595-Met 596 to Asp~aS-Leu 506, seen in Swedish familial 
~_D, where the enhanced production of AI~ is due to the in- 
teased efficiency of cleavage at the mutated [~-secretase ite 
114] and the consequent unsusceptibility (see below) of the 
esulting 12-kDa fragment o cx-secretase cleavage [15,16]. 
['he Ap production pathway in Swedish familial AD, however, 
s qualitatively different from that responsible for the produc- 
ion of Ap from wild-type pAPP in that Leu596/Asp 597 clea- 
,age occurs in a different cellular compartment [14,15] and 
~ossibly by a different enzyme [15], and therefore is not rele- 
,ant to AI~ production in sporadic, i.e. involving wild-type 
APP, AD where there is no evidence that proteolytic path- 
ray leading to the production of A~ differs qualitatively or 
iuantitatively from that occurring in normal cells. Therefore, 
.ince proteolytic processing alone cannot account for the in- 
:reased production of A~ in sporadic AD, an additional Ap 
~roduction pathway may be employed in this type of AD, 
~vhich constitutes the majority of all AD cases. How could 
his new mechanism operate? To answer this question, one 
;hould consider factors which may influence the production 
)f Ap. 
The major factor that dramatically limits the gencration of 
k13 in normal cells is cleavage of I~APP at the c~-secrctasc site 
~vhich precludes the formation of A~. Can this cleavage be 
tvoided? The answer is affirmative: whereas the intact ~APP 
s a substrate for cleavagc at the c~-secretase site, the 12-kDa 
2-terminal ~APP fragment containing Ap at its N-tcrminus is 
mt susceptiblc to the c¢-secretase cleavage. What is the rela- 
ionship between the 12-kDa C-terminal fragment of 13APP 
md Ap? The amount of the 12-kDa C-terminal I~APP flag- 
nent correlates with thc amount of released A~ [17,18], indi- 
:ative of the precursor-product relationship. Direct evidence 
hat the 12kDa C-terminal 13APP fragment is the immediate 
~)recursor of A~ and can bc furthcr cleaved by y-secretasc, 
:hus generating A~, comes from work of Dyrks and co-work- 
~'rs, who transfected cells with a 5'-truncated ~APP gcne 
16,19]. RNA transcribed from transfccted DNA was trans- 
ated starting at Met ~96 and rcsulting in an extensive over- 
)roduction of the 12-kDa C-terminal ~APP fragment with 
19] or without [16] signal sequencc. In both cases, this frag- 
nent was rapidly clcavcd by 7-secrctase to generate Ap, which 
~as subsequently secreted. Importantly, the 12-kDa C-ter- 
ninal I~APP fragment, expressed in transfccted cells indepen- 
iently of 13APP, was not cleaved at the cc-secretasc site [16,20]. 
this observation is consistent with results obtained by Haass 
md co-workers, who demonstrated that cleavage of ~APP at 
he 13-secretase site appears to prevent cleavage at the c~-secre- 
ase site [15]. The same experiments [15,16,20] also lead to 
mother important conclusion, namely that cleavage at the y- 
~ecretase sitc is not thc ratc-limiting step in the production of 
~p. Thc facts that the 12-kDa C-terminal ~APP fragment, thc 
immcdiate precursor of A~, is not susceptible to cleavagc at 
~he c~-secretase site and that cleavage at the 7-secretase site is 
not the rate-limiting step in the generation of A~ suggest that 
the increase in production of the 12-kDa C-terminal pAPP 
fragment may be an efficient way to overproduce Ap. The 
most effective manner to achieve this would be generation 
of the 12-kDa fragment independently of ~APP. How could 
such a process be accomplished? 
2. The model 
In I~APP mRNA, the A~-coding segment is preceded imme- 
diately by the in-frame AUG codon at position 1786 (nucleo- 
tide residues are numbered from the start of the I3APP coding 
region as in [21]) corresponding to the Met 596. The initiation 
of translation at this position would produce the 12-kDa C- 
terminal pAPP fragment independently of pAPP. It is note- 
worthy that the AUG]T86 is situated within a nucleotide con- 
text optimal for initiation of translation, i.e. an A in position 
-3  and a G in position +4 relative to the A of the AUG 
codon [22]. In fact, AUG1786 is one of only two AUG codons 
within the entire ~APP mRNA which are located within an 
optimal translation initiation context. Such favorable location 
of AUG1786 was the basis for an earlier proposal that the 12- 
kDa C-terminal fragment may be generated independently 
from ~APP by internal initiation of translation of the intact 
[~APP mRNA at the AUG]Ts6 [23], but this has been subse- 
quently ruled out by the elegant experiments of Citron and 
co-workers [24]. There is, however, another possibility of utili- 
zation of the A UG1786 as a translation initiation codon, namely 
the generation of a 5'-truncated pAPP mRNA in which the 
A UG1786 becomes thefirst AUG codon. A possible mechanism 
for the generation of such a truncated pAPP mRNA is sug- 
gested by recent results from the author's laboratory with 
globin mRNA in erythroid precursor cells [25]. 
Recently, we obtained evidence that, in erythroid cells, glo- 
bin mRNA can be produced by RNA-dependent RNA syn- 
thesis via antisense RNA intermediates and that this process 
may also occur in other cell types with other mRNA species. 
Elucidation of the structure of antisense globin RNA sug- 
gested a possible mechanism [25] illustrated in Fig. 2. Syn- 
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Fig. 2. Postulated mechanism of cellular mRNA replication. Box, 
sense strand; line, antisense strand. A' and a', complementary ele- 
ments within an antisense strand. Note that the A' element is 
strictly 3'-terminal. See details in text. 
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thesis of antisense RNA is initiated within the poly(A) region 
of mRNA, presumably by a mechanism similar to that em- 
ployed in viral systems [26]; consequently, it contains a 
poly(U) stretch at the 5' end. At the 3' end, antisense RNA 
contains two strongly complementary elements within the seg- 
ment corresponding to the 5'-untranslated region of globin 
mRNA. This complementarity within the antisense strand is 
highly conserved uring evolution [27] and extends not only 
to the presence of complementary elements but also to their 
position, the complementary elements being always located 
within the segment of antisense strand corresponding to the 
5'-untranslated region of globin mRNA, one always being 
strictly Y-terminal [27]. The strong evolutionary conservation 
suggested an underlying function, namely the priming of the 
synthesis of a sense RNA strand by the Y-terminal element of 
an antisense strand. The strict 3'-terminal location of one of 
the complementary elements appears to be an absolute re- 
quirement, he addition of only one 'noncomplementary' nu-
cleotide to the 3' terminus of the antisense globin strand 
strongly inhibiting its self-priming capacity [27]. The initial 
product of such a self-priming process is a chimeric anti- 
sense-sense molecule in the form of a hairpin loop (Fig. 2). 
The separation of strands appears to involve cleavage at the 3' 
end of the loop that generates 5'-truncated mRNA molecules. 
Since a full-size mRNA molecule can be repeatedly used as a 
template in such a process, it can direct the synthesis of many 
truncated mRNA molecules; the subsequent translation of 
this RNA would result in enhanced production of a polypep- 
tide. Potentially, this process, which may have evolved to en- 
hance expression of specific genes, may be involved in dis- 
eases, such as AD, associated with the overproduction of 
specific proteins. 
Because self-priming by globin antisense RNA occurs with- 
in the segment corresponding to the 5' untranslated region of 
mRNA, the resulting sense strand is truncated within its 5' 
untranslated region but retains an intact coding capacity. Re- 
cently, we identified antisense counterparts, putative inter- 
mediates in RNA-dependent RNA synthesis, for a number 
of spliced mRNA species in mammalian cells, an indication 
that this phenomenon may be quite widespread. Principally, 
in non-globin systems, self-priming might occur within a por- 
tion of an antisense molecule corresponding to the coding 
region of an mRNA thus generating sense strand with 5'- 
truncated coding region. In such a case, provided the first 
available AUG is in-frame, translation would result in the 
C-terminal portion of an original polypeptide. If the ~APP 
mRNA were subject o such a replication process and if trun- 
cation occurred so that the first available AUG is the 
AUGlrs6, translation would result in the 12-kDa C-terminal 
fragment of ~APP. 
For a 5'-truncated ~APP mRNA with the first AUG codon 
in position 1786 to be produced by the mechanism described 
above, the antisense ~APP RNA should be able to self-prime 
the synthesis of a sense-strand in a manner illustrated in Fig. 
2, starting upstream from and in the vicinity of the AUG17s6. 
For this to occur, the antisense strand would have to contain 
two topologically compatible complementary elements, one 
strictly Y-terminal and another corresponding to a segment 
of ~APP mRNA upstream of the AUGlr86. Is this require- 
ment satisfied in a complement of ~APP mRNA? An answer 
to this question could be obtained in a model experiment of a 
type carried out with globin mRNA [27]. In such an experi- 
ment, an mRNA of interest serves as a template for synthesis 
of cDNA (the antisense strand) and is subsequently removed 
by RNase H activity usually present in preparations of reverse 
transcriptase. If complementary elements were present within 
the antisense strand, if one of them were Y-terminal and if 
they were topologically compatible, self-priming of sense 
strand synthesis would occur. The result would be an anti- 
sense strand (cDNA) extended at the 3' end by a segment of a 
sense strand in a hairpin-like structure. Moreover, provided 
that the 5' terminus of an mRNA were defined, the junction 
between the antisense and sense components would indicate 
the site of self-priming. 
In fact, such an experiment was actually carried out with 
~APP mRNA. In 1988, when several ~APP cDNAs had al- 
ready been obtained but the sequence of the gene and its 
flanking regions were not yet known, a new ~APP cDNA 
was reported [28]. It differed from the others in that it con- 
tained, in addition to a known complement of ~APP mRNA, 
an over 70-nucleotide-long segment at the 3' end. When the 5' 
end of the 9APP gene and its flanking regions were sequenced 
[29], no genomic sequence corresponding to the additional 3' 
segment of the new cDNA could be seen. On the other hand, 
it was found that the non-coded segment of the new cDNA 
was identical to a segment of ~APP mRNA within the coding 
region of the molecule about 2 kb downstream from its 5' 
terminus which overlaps in part with the A~ coding region 
[30]. This unusual ~APP cDNA can be analyzed in terms of 
our model for RNA-dependent RNA synthesis (Fig. 2). It 
consists of an antisense molecule (cDNA), extended by a 
sense-strand fragment identical to the segment of ~APP 
mRNA immediately downstream from residue 1728. It can 
thus be viewed as a chimeric antisense-sense molecule in which 
a hairpin loop connects a segment of the antisense portion 
with a complementary sense extension, which corresponds to 
a segment of the coding region of ~APP mRNA. Such an 
extension could have been triggered, upon completion of 
cDNA synthesis [27], by complementarity of the Y-terminal 
segment of ~APP antisense strand with a topologically com- 
patible internal fragment of the same molecule corresponding 
to a segment of ~APP mRNA immediately upstream of nu- 
cleotide 1728. 
As shown in Fig. 3a, such complementary elements are 
indeed present within the antisense ~APP strand. Because 
one of the elements must be strictly Y-terminal to initiate 
the extension [27], the self-priming ability of the antisense 
strand depends critically on the 5'-terminal sequence of 
~APP mRNA. There are at least five known 5' ends of 
~APP mRNA in normal brain [29]. The corresponding 3'- 
ends of antisense strands are marked by dots in Fig. 3a. 
Only one of these, i.e. -149 in Fig. 3, would allow effective 
self-priming to yield the chimeric antisense-sense molecule - 
with other ends the 3' complementary dement would be either 
non-terminal or form an unstable hybrid. In normal subjects 
the predominant transcription start site is at residue -146 and 
whether it shifts in AD patients to residue -149 or elsewhere 
remains to be determined. Cleavage at the 3' end of a hairpin 
loop (Fig. 3b) of the chimeric antisense-sense ~APP molecule 
would generate a severely 5'-truncated sense ~APP RNA mol- 
ecule in which the first AUG codon, AUGlrs6 corresponding 
to Met 596, is in frame with and immediately precedes the A9 
coding region. Translation of the 5'-truncated ~APP mRNA 
would result, therefore, in the 12-kDa C-terminal portion of 
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7'his polypeptide could be processed further by two known 
enzymes to generate A~: N-terminal methionine aminopepti- 
<ase [31], which removes N-terminal methionine from a ma- 
j ~rity of newly synthesized eukaryotic proteins, and 7-secre- 
l.tse. Indeed, as was mentioned above, the 12-kDa C-terminal 
I~APP fragment, translated in transfected cells from Met 596 
without a leader sequence, is cleaved proteolytically at the %,- 
szcretase site to generate A~, which is subsequently secreted 
[6]. 
3. Predictions and conclusions 
The model for antisense RNA-mediated generation of a 5'- 
t,'uncated ~APP mRNA encoding the 12-kDa C-terminal 
I, APP fragment, a process postulated to be activated or en- 
t anced in AD-affected tissues, allows several verifiable predic- 
t,ons. These include the following for sporadic AD-affected 
brain tissues: (i) the presence of the antisense ~APP RNA, 
~ome of it specifically truncated at the 3' terminus; (ii) shift 
~.f the transcriptional start site for ~APP mRNA to position 
-149 or downstream from position -143; (iii) the occurrence 
~f a 5'-truncated pAPP mRNA encoding the 12-kDa C-ter- 
1 linal fragment of [~APP; (iv) the presence of RNA-dependent 
]~NA polymerase activity. 
Another prediction of the proposed model is the extensive 
synthesis of the 12-kDa C-terminal [~APP fragment as a pri- 
11ary translational product in A~-overproducing cells, a phe- 
i omenon that should be seen in a pulse-chase xperiment. 
t~urrently, however, this prediction cannot be verified for 
ltck of an experimental model system for sporadic AD. 
It should be noted that two technical aspects could compli- 
ate the investigation of the proposed mechanism. Firstly, A~- 
, verproducing cells are likely to be the first victims of AD 
~europathology triggered by increased deposition of Ap. 
'i'herefore, in post-mortem samples from patients with ad- 
'~anced AD, A~-overproducing cells may be poorly repre- 
sented. A possible solution to this potential problem is to 
, nalyze a sufficient number of samples from 'normal' subjects, 
, ld enough to have relatively high probability of developing 
xD. Secondly, by analogy with globin mRNA replication in 
Lrythroid precursor cells ([25]; V. Volloch, unpublished re- 
sults), 5'-truncated ~APP mRNA encoding the 12-kDa 
lAPP fragment may be heavily modified and consequently 
hybridize poorly with specific probes at high stringency con- 
ditions. Therefore, an initial search for ~APP antisense RNA 
appears to be the most efficient way to pursue this proposal. 
In summary, the overproduction of A~ appears to be the 
primary cause of AD. In some cases it is caused by mutations 
within the pAPP gene that affect pAPP proteolytic pathway. 
In such familial AD cases, mutation-mediated nhancement 
or alteration of proteolytic leavage is sufficient for the in- 
creased production of A~ and there is no need to invoke 
additional mechanisms beside the mutations. The best exam- 
ple to illustrate this point is the Swedish mutation where the 
mechanism proposed here cannot operate because Met 596 is 
replaced by Leu. But neither the proposed nor any other 
additional mechanism is needed in this case; the mutation 
alone is sufficient. Indeed, the enhanced production of A[~ in 
Swedish familial AD is due to the increased efficiency of cleav- 
age at the mutated [3-secretase ite [14] and the consequent 
unsusceptibility of the resulting 12-kDa fragment o the ~- 
secretase cleavage [15,16,20]. The A~ production pathway in 
Swedish familial AD, however, is qualitatively different from 
and therefore not relevant o A~ production in sporadic AD 
[15]. On the other hand, there is no evidence that proteolytic 
processing of [~APP leading to the production of A~ in spora- 
dic AD differs qualitatively or quantitatively from that occur- 
ring in normal tissues, indicating that an additional A~ pro- 
duction pathway may be employed. A mechanism is described 
in this paper for the ~APP-independent generation and over- 
production of the 12-kDa C-terminal fragment of pAPP, the 
immediate precursor of the A~. It proposes the occurrence of 
antisense RNA-mediated generation of 5'-truncated [3APP 
mRNA followed by initiation of translation at the AUG1786 
immediately preceding the Ap-coding region. It requires a 
shift of the transcriptional start site of ~APP mRNA and 
induction of RNA-dependent RNA synthesis machinery in 
response to an undefined stimulus and is postulated to be 
activated or enhanced in sporadic AD in the age-dependent 
and tissue-specific manner. In this model two factors contri- 
bute to the increased production of A[~: (i) the proposed 
mechanism for generation of 5'-truncated ~APP mRNA leads 
to its overproduction; and (ii) in contrast o the intact ~APP, 
where cleavage at the the ~-secretase ite precludes formation 
of A~, 12-kDa C-terminal [3APP fragment, the primary trans- 
lation product of the proposed mechanism, is not a subject o 
c~-secretase cleavage, but is cleaved by 7-secretase. This cleav- 
age generates A~ which is subsequently secreted. The pro- 
posed model makes several verifiable predictions and suggests 
128 V. VolIoch/FEBS Letters 390 (1996) 124-128 
new directions of experimentation that may lead to a better 
understanding of the mechanisms involved in AD. 
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